Current management of PC has very low cost-effectiveness
A recent large European study showed that to prevent one death from PC by PSA screening, 1400 men without symptoms had to undergo systematic PSA testing and 48 men had to undergo surgery (prostatectomy).
A genetic test that can identify individuals with high risk of developing PC (<20% of all men) will, as a consequence, lead to less testing in those at low risk and better follow-up in those at high risk. This may reduce or even prevent overdiagnosis of PC caused by excessive PSA testing, which is very important in Denmark and other parts of the world, where opportunistic PSA screening requested by patients without symptoms of PC is becoming increasingly common, especially in general practice.
This creates a very heavy and continuously growing burden on the health care system due to increased demands for general practitioners, specialized urologist, and hospital visits.
We are not aware of other studies worldwide that include general practitioners, urologists and molecular biologists as well as bioinformaticians to translate the genetic findings into a useful clinical approach. The unique public Danish health care system structure is a great advantage for this.
Prostate cancer aggressiveness markers
Identification of new biomarkers that can distinguish aggressive from non-aggressive PC will also be of immense importance hereby allowing us to reduce or even prevent overtreatment of PC to the benefit of patient quality of life and health care expenses.
Preferentially, such a set of biomarkers should be embedded in a nomogram including other clinical parameters for easy clinical use. The global market for improved molecular diagnostic tests for PC is very large, due to the limitations of currently available tests. Thus, intellectual protection of identified biomarkers will be relevant.
CLC bio will expand their software developed in the project to establish a cancer research and diagnostics module. The module will be sold as a highly specialized add-on to CLC bio’s existing NGS data analysis platform. Target customers are pharmaceutical and biotechnological companies, hospitals and universities.